Top

30-10-2024 | Breast Cancer | Review

Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis

Authors: Larissa Vaz-Goncalves, Melinda M. Protani, Jodi M. Saunus, Graham A. Colditz, Marina M. Reeves

Published in: Breast Cancer Research and Treatment

Abstract

Purpose

The association between obesity and triple-negative breast cancer (TNBC) prognosis has been equivocal, with considerable heterogeneity between and within studies. Recent meta-analyses report adverse associations with overall survival (OS) and disease-free survival (DFS) in TNBC. We update this evidence and examine study- and disease-specific sources of heterogeneity.

Methods

A systematic search of four databases was conducted until February 22, 2023. Random-effects meta-analyses were used to pool hazard ratios (HR) for OS, DFS, and breast cancer-specific mortality (BCSM). Subgroup analyses examined sources of study heterogeneity.

Results

In meta-analyses of included studies (n = 33), significant associations were observed between excess body weight and worse OS (n = 24; HR = 1.20; 95%CI 1.20–1.34), DFS (n = 26; HR = 1.15; 1.05–1.27), and BCSM (n = 9; HR = 1.13; 1.00–1.27). In subgroup meta-analyses, significant inter-study survival differences were observed for study location (OS, DFS), time period of diagnoses (DFS), menopausal status (OS), and body mass index cut points examined (OS). Asian and European studies reported significant associations with OS (HR = 1.31; 1.11–1.54 and HR = 1.38; 1.00–1.89, respectively) and DFS (HR = 1.28; 1.07–1.54 and HR = 1.44; 1.13–1.84, respectively); however, no association was observed between obesity and TNBC prognosis in North American studies (OS: HR = 1.03; 0.89–1.19; DFS: HR = 1.05; 0.95–1.15). Location subgroup differences remained robust after excluding poor-quality studies. Post hoc analysis in the subset of studies reporting predominantly (≥ 70%) White sample showed no statistically significant associations for OS (HR = 1.13; 95%CI 0.96, 1.34), DFS (HR = 1.03; 95%CI 0.86, 1.23), or BCSM (HR = 1.08; 95%CI 0.91, 1.27).

Conclusion

This study further confirms that obesity is associated with poor prognosis in TNBC and identified subgroups at higher risk. Ethnic differences in the association between excess body weight and TNBC are reported. Further exploration of study and patient characteristics is needed to properly understand the populations most at risk.

Available only for authorised users

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. https://doi.org/10.1001/jama.295.21.2492CrossRefPubMed

Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279–287. https://doi.org/10.1007/s10549-016-4059-6CrossRefPubMed

Jatoi I, Sung H, Jemal A (2022) The emergence of the racial disparity in U.S. breast-cancer mortality. N Engl J Med 386(25):2349–2352. https://doi.org/10.1056/NEJMp2200244CrossRefPubMed

Maqbool M, Bekele F, Fekadu G (2022) Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer 14:15–24. https://doi.org/10.2147/bctt.S348060CrossRefPubMedPubMedCentral

Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914. https://doi.org/10.1093/annonc/mdu042CrossRefPubMedPubMedCentral

Niraula S, Ocana A, Ennis M, Goodwin PJ (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134(2):769–781. https://doi.org/10.1007/s10549-012-2073-xCrossRefPubMed

Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635. https://doi.org/10.1007/s10549-010-0990-0CrossRefPubMed

Jiralerspong S, Goodwin PJ (2016) Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 34(35):4203–4216. https://doi.org/10.1200/JCO.2016.68.4480CrossRefPubMed

Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ (2021) Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djab023CrossRefPubMedPubMedCentral

10.

Harborg S, Zachariae R, Olsen J, Johannsen M, Cronin-Fenton D, Bøggild H, Borgquist S (2021) Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis. NPJ Breast Cancer 7(119):1–9. https://doi.org/10.1038/s41523-021-00325-6CrossRef

11.

Swisher AK, Abraham J, Bonner D, Gilleland D, Hobbs G, Kurian S et al (2015) Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile. Support Care Cancer 23(10):2995–3003. https://doi.org/10.1007/s00520-015-2667-zCrossRefPubMedPubMedCentral

12.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://doi.org/10.1186/2046-4053-4-1CrossRefPubMedPubMedCentral

13.

Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2014) Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat 146(1):189–197. https://doi.org/10.1007/s10549-014-3002-yCrossRefPubMed

14.

Feliciano EMC, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL et al (2017) Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. Cancer 123(13):2535–2542. https://doi.org/10.1002/cncr.30637CrossRef

15.

Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A et al (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized Success a trial. Breast Cancer Res 17(129):1–11. https://doi.org/10.1186/s13058-015-0639-3CrossRef

16.

Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J et al (2013) Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 15(105):1–14. https://doi.org/10.1186/bcr3572CrossRef

17.

Hamling J, Lee P, Weitkunat R, Ambühl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27(7):954–970. https://doi.org/10.1002/sim.3013CrossRefPubMed

18.

Wells GAS B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

19.

Newcastle-Ottawa Quality Assessment Form for Cohort Studies [Available from: https://www.ncbi.nlm.nih.gov/books/NBK115843/bin/appe-fm3.pdf.

20.

StataCorp. 2021 Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC

21.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2CrossRefPubMed

22.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Journal Bmj 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMed

23.

Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463. https://doi.org/10.1111/j.0006-341x.2000.00455.xCrossRefPubMed

24.

van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21(4):589–624. https://doi.org/10.1002/sim.1040CrossRefPubMed

25.

Alluri P, Newman LA (2014) Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am 23(3):567–577. https://doi.org/10.1016/j.soc.2014.03.003CrossRefPubMedPubMedCentral

26.

Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7(127):1–15. https://doi.org/10.1186/1471-2164-7-127CrossRef

27.

Sahin S, Erdem GU, Karatas F, Aytekin A, Sever AR, Ozisik Y, Altundag K (2017) The association between body mass index and immunohistochemical subtypes in breast cancer. Breast 32:227–236. https://doi.org/10.1016/j.breast.2016.09.019CrossRefPubMed

28.

Lu Y, Ma H, Malone KE, Norman SA, Sullivan-Halley J, Strom BL et al (2011) Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 29(25):3358–3365. https://doi.org/10.1200/jco.2010.34.2048CrossRefPubMedPubMedCentral

29.

Kwan ML, John EM, Caan BJ, Lee VS, Bernstein L, Cheng I et al (2014) Obesity and mortality after breast cancer by race/ethnicity: the california breast cancer survivorship consortium. Am J Epidemiol 179(1):95–111. https://doi.org/10.1093/aje/kwt233CrossRefPubMed

30.

Ballinger TJ, Jiang G, Shen F, Miller KD, Sledge GW Jr, Schneider BP (2022) Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103). Cancer 128(11):2174–2181. https://doi.org/10.1002/cncr.34173CrossRefPubMed

31.

Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H et al (2021) Breast cancer risk factors and survival by tumor subtype: pooled analyses from the breast cancer association consortium. Cancer Epidemiol Biomark Prev 30(4):623–642. https://doi.org/10.1158/1055-9965.Epi-20-0924CrossRef

32.

Mowad R, Chu QD, Li BD, Burton GV, Ampil FL, Kim RH (2013) Does obesity have an effect on outcomes in triple-negative breast cancer? J Surg Res 184(1):253–259. https://doi.org/10.1016/j.jss.2013.05.037CrossRefPubMed

33.

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju055CrossRefPubMedPubMedCentral

34.

Du X (2022) Racial disparities in health insurance, triple-negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States. Mol Clin Oncol 16(95):1–12. https://doi.org/10.3892/mco.2022.2528CrossRef

35.

Kwong A, Mang OW, Wong CH, Chau WW, Law SC (2011) Breast cancer in Hong Kong, Southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients: 1997–2001. Ann Surg Oncol 18(11):3072–3078. https://doi.org/10.1245/s10434-011-1960-4CrossRefPubMedPubMedCentral

36.

Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17(2):118–124. https://doi.org/10.1007/s12282-009-0113-0CrossRefPubMed

37.

Kulkarni A, Kelkar DA, Parikh N, Shashidhara LS, Koppiker CB, Kulkarni M (2020) Meta-Analysis of prevalence of triple-negative breast cancer and its clinical features at incidence in indian patients with breast cancer. JCO Glob Oncol 6:1052–1062. https://doi.org/10.1200/go.20.00054CrossRefPubMed

38.

Sim X, Ali RA, Wedren S, Goh DL, Tan CS, Reilly M et al (2006) Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968–2002. BMC Cancer 6(261):1–11. https://doi.org/10.1186/1471-2407-6-261CrossRef

39.

Sung H, Rosenberg PS, Chen WQ, Hartman M, Lim WY, Chia KS et al (2016) The impact of breast cancer-specific birth cohort effects among younger and older Chinese populations. Int J Cancer 139(3):527–534. https://doi.org/10.1002/ijc.30095CrossRefPubMedPubMedCentral

40.

Zhai F, Wang H, Du S, He Y, Wang Z, Ge K, Popkin BM (2007) Lifespan nutrition and changing socio-economic conditions in China. Asia Pac J Clin Nutr 16(1):374–382PubMed

41.

Misra A, Singhal N, Sivakumar B, Bhagat N, Jaiswal A, Khurana L (2011) Nutrition transition in India: secular trends in dietary intake and their relationship to diet-related non-communicable diseases. J Diabetes 3(4):278–292. https://doi.org/10.1111/j.1753-0407.2011.00139.xCrossRefPubMed

42.

Zhang R, Wang Z, Fei Y, Zhou B, Zheng S, Wang L et al (2015) The difference in nutrient intakes between chinese and mediterranean. Jpn Am Diets Nutr 7(6):4661–4688. https://doi.org/10.3390/nu7064661CrossRef

43.

Deurenberg P, Deurenberg-Yap M, Guricci S (2002) Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 3(3):141–146. https://doi.org/10.1046/j.1467-789x.2002.00065.xCrossRefPubMed

44.

Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R (1996) Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 45(9):1119–1124. https://doi.org/10.1016/s0026-0495(96)90011-6CrossRefPubMed

45.

Conway JM, Yanovski SZ, Avila NA, Hubbard VS (1995) Visceral adipose tissue differences in black and white women. Am J Clin Nutr 61(4):765–771. https://doi.org/10.1093/ajcn/61.4.765CrossRefPubMed

46.

Hales CM, Carroll MD, Fryar CD, Ogden CL (2020) Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief 360:1–8

47.

McTigue KM, Garrett JM, Popkin BM (2002) The natural history of the development of obesity in a cohort of young U.S. adults between 1981 and 1998. Ann Intern Med 136(12):857–864. https://doi.org/10.7326/0003-4819-136-12-200206180-00006CrossRefPubMed

48.

Wulan SN, Westerterp KR, Plasqui G (2010) Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas 65(4):315–319. https://doi.org/10.1016/j.maturitas.2009.12.012CrossRefPubMed

49.

Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH et al (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368(9548):1681–1688. https://doi.org/10.1016/s0140-6736(06)69703-1CrossRefPubMed

50.

Narayan KMV, Kanaya AM (2020) Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. Diabetologia 63(6):1103–1109. https://doi.org/10.1007/s00125-020-05132-5CrossRefPubMedPubMedCentral

51.

Lear SA, Chockalingam A, Kohli S, Richardson CG, Humphries KH (2012) Elevation in cardiovascular disease risk in South Asians is mediated by differences in visceral adipose tissue. Obesity 20(6):1293–1300. https://doi.org/10.1038/oby.2011.395CrossRefPubMed

52.

World Health Organization (2000) The asia-pacific perspective: redefining obesity and its treatment. Regional Office for Western Pacific, Sydney, p 55

53.

Gallagher D, Visser M, Sepúlveda D, Pierson RN, Harris T, Heymsfield SB (1996) How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 143(3):228–239. https://doi.org/10.1093/oxfordjournals.aje.a008733CrossRefPubMed

54.

Bray GA (2023) Beyond BMI. Nutrients. https://doi.org/10.3390/nu15102254CrossRefPubMedPubMedCentral

55.

Chen HL, Ding A, Wang ML (2016) Impact of central obesity on prognostic outcome of triple negative breast cancer in Chinese women. Springerplus 5:594. https://doi.org/10.1186/s40064-016-2200-yCrossRefPubMedPubMedCentral

56.

Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA (2015) Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. Cancer Causes Control 26(12):1803–1811. https://doi.org/10.1007/s10552-015-0673-6CrossRefPubMedPubMedCentral

57.

Lofterød T, Frydenberg H, Veierød MB, Jenum AK, Reitan JB, Wist EA, Thune I (2022) The influence of metabolic factors and ethnicity on breast cancer risk, treatment and survival: the Oslo ethnic breast cancer study. Acta Oncol 61(5):649–657. https://doi.org/10.1080/0284186x.2022.2053573CrossRefPubMed

58.

Stierman B AJ, Carroll MD, Chen T, Davy O, Fink S, et al (2021) National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files—Development of Files and Prevalence Estimates for Selected Health Outcomes. (158):1–21

59.

Barba T, Deurenberg P et al (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163. https://doi.org/10.1016/s0140-6736(03)15268-3CrossRef

60.

Kaul K, Misri S, Ramaswamy B, Ganju RK (2021) Contribution of the tumor and obese microenvironment to triple negative breast cancer. Cancer Lett 509:115–120. https://doi.org/10.1016/j.canlet.2021.03.024CrossRefPubMed

61.

Sun HZJ, Chen L, Zu X, Wen G, Zhong J (2017) Triple-negative breast cancer and its association with obesity (Review). Mole Clin Onlcol 7(6):935–942. https://doi.org/10.3892/mco.2017.1429CrossRef

62.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147CrossRefPubMed

63.

Caan BJ, Cespedes Feliciano EM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4(6):798–804. https://doi.org/10.1001/jamaoncol.2018.0137CrossRefPubMedPubMedCentral

64.

Cortet M, Bertaut A, Molinié F, Bara S, Beltjens F, Coutant C, Arveux P (2018) Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries. BMC Cancer 18(1):161. https://doi.org/10.1186/s12885-018-4080-8CrossRefPubMedPubMedCentral

65.

Cossetti RJ, Tyldesley SK, Speers CH, Zheng Y, Gelmon KA (2015) Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol 33(1):65–73. https://doi.org/10.1200/jco.2014.57.2461CrossRefPubMed

66.

World Cancer Research Fund/American Institute for Cancer Research. Survivors of breast cancer and other cancers (2018) London2018 Available from: https://www.wcrf.org/wp-content/uploads/2021/02/Cancer-Survivors.pdf.

67.

Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT et al (2014) American society of clinical oncology position statement on obesity and cancer. J Clin Oncol 32(31):3568–3574. https://doi.org/10.1200/jco.2014.58.4680CrossRefPubMedPubMedCentral

68.

Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB (2011) Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer 117(18):4132–4140. https://doi.org/10.1002/cncr.26019CrossRefPubMed

69.

Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364–372. https://doi.org/10.1016/j.clbc.2012.07.013CrossRefPubMed

70.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118(23):5937–5946. https://doi.org/10.1002/cncr.27527CrossRefPubMed

71.

Asaga S, Kinoshita T, Hojo T, Suzuki J, Jimbo K, Tsuda H (2013) Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy. Clin Breast Cancer 13(1):40–46. https://doi.org/10.1016/j.clbc.2012.09.013CrossRefPubMed

72.

Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F et al (2013) The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J buon 18(2):335–341PubMed

73.

Fan Y, Ding X, Wang J, Ma F, Yuan P, Li Q et al (2015) Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs. Int J Biol Markers 30(2):e200–e207. https://doi.org/10.5301/jbm.5000143CrossRefPubMed

74.

Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM (2015) Overweight as a prognostic factor for triple-negative breast cancers in Chinese Women. PLoS ONE 10(6):e0129741. https://doi.org/10.1371/journal.pone.0129741CrossRefPubMedPubMedCentral

75.

Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W et al (2015) Body Mass Index, PAM50 subtype, and outcomes in node-positive breast cancer: CALGB 9741 (Alliance). J Natl Cancer Inst 107(9):1–7. https://doi.org/10.1093/jnci/djv179CrossRef

76.

Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ (2015) Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer 15(865):1–9. https://doi.org/10.1186/s12885-015-1879-4CrossRef

77.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP et al (2015) Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by neoadjuvant chemotherapy. PLoS ONE 10(12):1–15. https://doi.org/10.1371/journal.pone.0144359CrossRef

78.

Bao PP, Cai H, Peng P, Gu K, Su Y, Shu XO, Zheng Y (2016) Body mass index and weight change in relation to triple-negative breast cancer survival. Cancer Causes Control 27(2):229–236. https://doi.org/10.1007/s10552-015-0700-7CrossRefPubMed

79.

Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K et al (2016) Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med 5(6):1328–1340. https://doi.org/10.1002/cam4.678CrossRefPubMedPubMedCentral

80.

Al Jarroudi O, Abda N, Seddik Y, Brahmi SA, Afqir S (2017) Overweight is it a prognostic factor in women with triple-negative breast cancer? Asian Pac J Cancer Prev 18(6):1519–1523. https://doi.org/10.22034/apjcp.2017.18.6.1519CrossRefPubMed

81.

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ et al (2017) Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28(7):1560–1568. https://doi.org/10.1093/annonc/mdx152CrossRefPubMedPubMedCentral

82.

Shaitelman SF, Stauder MC, Allen P, Reddy S, Lakoski S, Atkinson B et al (2017) Impact of Statin use on outcomes in triple negative breast cancer. J Cancer 8(11):2026–2032. https://doi.org/10.7150/jca.18743CrossRefPubMedPubMedCentral

83.

Cho WK, Choi DH, Park W, Cha H, Nam SJ, Kim SW et al (2018) Effect of body mass index on survival in breast cancer patients according to subtype, metabolic syndrome, and treatment. Clin Breast Cancer 18(5):e1141–e1147. https://doi.org/10.1016/j.clbc.2018.04.010CrossRefPubMed

84.

Liu YL, Saraf A, Catanese B, Lee SM, Zhang Y, Connolly EP, Kalinsky K (2018) Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. Breast Cancer Res Treat 167(1):277–288. https://doi.org/10.1007/s10549-017-4507-yCrossRefPubMed

85.

Abubakar M, Sung H, Bcr D, Guida J, Tang TS, Pfeiffer RM, Yang XR (2018) Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res 20(114):1–14. https://doi.org/10.1186/s13058-018-1033-8CrossRef

86.

Wang K, Wu YT, Zhang X, Chen L, Zhu WM, Zhang AJ et al (2019) Clinicopathologic and prognostic significance of body mass index (BMI) among breast cancer patients in western china: a retrospective multicenter cohort based on Western China Clinical Cooperation Group (WCCCG). Biomed Res Int 2019:3692093. https://doi.org/10.1155/2019/3692093CrossRefPubMedPubMedCentral

87.

Blair CK, Wiggins CL, Nibbe AM, Storlie CB, Prossnitz ER, Royce M et al (2019) Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. NPJ Breast Cancer 5(33):1–7. https://doi.org/10.1038/s41523-019-0128-4CrossRef

88.

Cárdenas-Cárdenas E, Tenorio-Torres A, Méndez JP, Orozco-Arguelles L, Leal-García M, Tejeda ME et al (2021) Different body mass indexes and their relation to prognosis of early-stage breast cancer in postmenopausal Mexican-Mestizo women. Women Health 61(2):210–217. https://doi.org/10.1080/03630242.2020.1812791CrossRefPubMed

89.

Kennard K, Buckley ME, Sizer LM, Larson S, Carter WB, Frazier TG, Carp NZ (2021) Metabolic syndrome: does this influence breast cancer outcomes in the triple-negative population? Breast Cancer Res Treat 186(1):53–63. https://doi.org/10.1007/s10549-020-06034-1CrossRefPubMed

90.

Kim SW, Chun M, Jung YS, Oh YT, Noh OK, Cho O (2021) Impact of body mass index on local recurrence according to intrinsic subtype approximation in korean women with early stage invasive breast cancer receiving contemporary treatments. J Cancer 12(15):4648–4654. https://doi.org/10.7150/jca.59064CrossRefPubMedPubMedCentral

Title: Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis
Authors: Larissa Vaz-Goncalves
Melinda M. Protani
Jodi M. Saunus
Graham A. Colditz
Marina M. Reeves
Publication date: 30-10-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Obesity
Obesity
Menopause
Published in: Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-024-07538-w

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma